"Genentech provides a highly collaborative, fast-paced and scientifically rigorous environment that allows people to grow both personally and professionally. The scientists here are driven to succeed, innovative and, most importantly, curious."
I joined Genentech in 2010 after being on staff at the University of Minnesota, College of Veterinary Medicine, working in the field of comparative cancer biology and pathology. I have always been interested in animal models of human disease, particularly cancer, and was increasingly motivated to transition from basic research to translational research where I could focus my efforts on developing cancer drugs for human patients. I was drawn to Genentech by its reputation for being scientifically rigorous and collaborative, as well as being highly successful at bringing novel oncology therapies to market. I have been working in cancer drug research and development, mainly on the antibody drug conjugate platform, since 2010.
My areas of interest and expertise are in comparative pathology, veterinary medicine, and cancer biology. I work in close collaboration with colleagues throughout safety assessment toxicology, nonclinical operations and research to drive the development of effective, safe, and novel oncology therapeutics. I am also actively involved with internal and cross-industry efforts focused on improving overall drug development efficiency. In addition, I regularly mentor veterinary students, residents and/or graduate students through externships and oversight of toxicologic pathology-related investigative studies.